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Background: Diffuse alveolar hemorrhage (DAH) represents a diagnostic challenge of acute
respiratory failure. Prompt identification of the underlying cause of DAH and initiation of
appropriate treatment are required in order to prevent acute respiratory failure and irrevers-
ible loss of renal function. More than 100 causes of DAH have been reported. However, the
relative frequency and the differential presentation of those causes have been poorly docu-
mented, as well as their respective prognosis.
Methods: We retrospectively reviewed the charts of 112 consecutive patients hospitalized for
DAH in a tertiary referral center over a 30-year period.
Results: Twenty-four causes of DAH were classified into four etiologic groups: immune
(n Z 39), congestive heart failure (CHF; n Z 33), miscellaneous (n Z 26), and idiopathic
DAH (n Z 14). Based on this classification, clinical and laboratory features of DAH differed
on hospital admission. Patients with immune DAH had more frequent pulmonary-renal
syndrome (p < 0.001), extra-pulmonary symptoms (p < 0.01), and lower blood hemoglobin
level than others (p < 0.001). Patients with CHF-related DAH were older and received moreneumologie et Re´animation, Hoˆpital Tenon, 4 rue de la Chine, 75970 Cedex 20 Paris, France. Tel.: þ33
.
n.aphp.fr (A. Parrot).
2 Elsevier Ltd. All rights reserved.
1022 N. de Prost et al.anticoagulant treatments than others (p < 0.05). Those with miscellaneous causes of DAH ex-
hibited a shorter prodromal phase (p < 0.001) and had more frequent hemoptysis >200 mL
(p < 0.05). Patients with idiopathic DAH had more bronchoalveolar lavage siderophages
(p < 0.01). In-hospital mortality was 24.1%, ranging from 7.1% in patients with idiopathic
DAH to 36.4% in those with CHF.
Conclusions: Arbitrary classification of DAH in four etiologic groups gives the opportunity to
underline distinct presentations and outcomes of various causes of DAH.
ª 2012 Elsevier Ltd. All rights reserved.Table 1 Etiology of DAH syndromes (N Z 112).
Immune N Z 39
Small-vessel vasculitides 28
Microscopic polyangiitis 16
Wegener’s granulomatosis 11
Churg and Strauss syndrome 1
ABMAD 5
Connective tissue disease 6
Systemic lupus erythematosus 4
Rheumatoid arthritis 1
Mixed connective tissue disease 1
Congestive heart failure N Z 33
Systolic dysfunction of the left ventriclea 20
Diastolic dysfunction of the left ventricle 8
Valvular heart diseaseb 5
Miscellaneous N Z 26
Infection 8
Staphylococcus aureusc 5
Leptospirosis 1
Anaerobic bacteria 1
Dirofilaria immitis 1
Barotrauma 6
Clotting disorder 6
Thrombocytopenia 3
Anticoagulant and/or antiaggregant
treatment
3
Cancerd 2
Uterine leiomyosarcoma 1
Small cell lung cancer 1
Toxic-induced DAH 2
Cannabis 1
Glue solvent inhalation 1
Drug-induced DAH 1
Clomifene 1
Fat embolisme 1
Idiopathic N Z 14
DAH, diffuse alveolar hemorrhage; ABMAD, anti-glomerular
basement membrane antibody disease.
a Due to Churg and Strauss syndrome in one patient, median
left ventricle ejection fraction was 40% (30e45).
b Mitral stenosis (n Z 4), aortic stenosis (n Z 1).
c Including two meticillin-resistant and three Panton-
Valentine leukocidin producing strains.
d DAH related to endovascular metastasis in both cases.
e Following a tibial fracture.Introduction
Diffuse alveolar hemorrhage (DAH), commonly defined as the
association of hemoptysis, new pulmonary infiltrates on
chest x-ray and anemia, is a rare syndrome resulting from
diffuse bleeding into the acinar portion of the lung.1,2
However, DAH can present in about 40% of the cases
without hemoptysis.3 DAH is a diagnostic and therapeutic
challenge because it may be revealed by nonspecific
pulmonary manifestations and caused by multiple immune
and non-immune disorders. Moreover, reported prognosis is
poor, with in-hospital mortality ranging from 20 to over
50%.4e6 Prompt identification of the underlying cause of DAH
and initiation of appropriate treatment is required in order
to prevent acute respiratory failure. When DAH is a mani-
festation of systemic illness, early targeted treatment can
also prevent the development of acute renal failure and the
potential subsequent renal death.7,8 The standard regimen
for remission induction of immune causes is based mainly on
high-dose steroids.9 However, such treatment will be inef-
fective and potentially deleterious if the DAH is due to non-
immune causes, such as congestive heart failure or infection.
Consequently, identification of the cause is crucial for
adequate management of a patient with DAH.
Over 100 causes of DAH have been reported in immu-
nocompetent patients (Table 1 of the online
supplement).1,3,10,11 Most of the published series focus
primarily on immune causes,2,5,8,12e14 but numerous non-
immune causes of DAH have been reported as case
reports.15e24 The relative frequency of the underlying
causes of DAH, as well as their respective prognosis, is not
well documented. We recently showed that the global
picture of DAH has changed over the last decades; non-
immune causes being largely underestimated.10 We also
reported similar outcome for immune and non-immune
causes. This finding challenged the belief that immune
DAH exhibits a worse prognosis than non-immune DAH.
Based on a retrospective cohort of 112 consecutive
immunocompetent patients, we aimed to report the causes
of DAH and their relative frequency and presentation to
a referral tertiary center in order to classify them into distinct
etiologic groups, and the mortality for each etiologic group.
Methods
Study design
A retrospective cohort study was performed in the Chest
Department including an Intensive Care Unit (ICU) of an
800-bed tertiary hospital in France (Hoˆpital Tenon,Assistance Publique-Hoˆpitaux de Paris, France). This
observational, non-interventional analysis of medical
Diffuse alveolar hemorrhage: Etiology and outcome 1023records was approved by the Institutional Review Board of
the French Learned Society for Respiratory Medicine -
Socie´te´ de Pneumologie de Langue Franc¸aise.
Inclusion criteria
The medical records of consecutive patients admitted
between January 1980 and December 2009 for suspected
DAH were reviewed. For patients with multiple admissions,
the first admission was used for the study. All adult patients
with symptomatic DAH were eligible. The definition of
symptomatic DAH was based on the following criteria. First,
the clinical and radiological presentation was compatible
with the diagnosis of DAH, including hemoptysis and/or new
pulmonary infiltrates on chest x-ray (Fig. 1A) and/or anemia
(i.e., DAH triad).2 Second, the bronchoalveolar lavage
(BAL) fluid was macroscopically bloody (Fig. 1B). Alterna-
tively, hemorrhagic and siderophagic alveolitis were evi-
denced on BAL cytology (Fig. 1C),19,25,26 trans-bronchial
lung biopsy or surgical lung biopsy.
Patients with immunocompromised status (human
immunodeficiency virus infection, hematological malig-
nancies, bone marrow or solid organ transplantation,
immunosuppressive drugs therapy, cytotoxic chemotherapy
or radiotherapy, steroids at a daily dose higher than 20 mg
of prednisone-equivalent for more than two months) were
excluded. Patients with hemorrhage of bronchial origin and
patients receiving hemodialysis for chronic renal failure
were also excluded.
Data collection
Data were abstracted from medical charts using a standard-
ized procedure (see the methods section of the online
supplement for more details). Variables available during
the first 24 h of hospitalization included demographics,Figure 1 A) Chest x-ray of a patient with diffuse alveolar hemorr
bloody bronchoalveolar lavage fluid. An increasing red blood cell cou
location is considered diagnostic of diffuse alveolar hemorrhage; C
method, showing deep blue throughout the cytoplasm of two alveo
references to colour in this figure legend, the reader is referred toclinical and laboratory features. Pulmonary-renal syndrome
was defined clinically by the presence of DAH and the
following criteria: hematuria, proteinuria > 1g/L, and
glomerular filtration rate (GFR)< 60mL/min. The prodromal
phase was the time elapsed between the first symptom
related to the cause of DAH and hospital admission. The
severity of DAH was assessed from generic scores of organ
dysfunction including the Logistic Organ Dysfunction (LOD)
score27 and the Simplified Acute Physiology Score (SAPS) II.28
Variables available during hospitalization included
hospital length of stay, vital status at hospital discharge,
need for invasive mechanical ventilation, hemodialysis,
blood transfusion, peak plasma lactic dehydrogenase (LDH)
level, anti-neutrophil cytoplasm antibody (ANCA)-test
immunofluorescence pattern (i.e., a granular cytoplasmic
neutrophil fluorescence with central interlobular accentu-
ation (c-ANCA), and a perinuclear fluorescence (p-ANCA))
and specificity (i.e., directed against proteinase-3 (PR3) or
myeloperoxydase (MPO), as detected by ELISA),29 lung and
kidney tissue histology and immunofluorescence analysis,
administration of steroids or cyclophosphamide, and insti-
tution of plasma exchange.
Variables available after hospital discharge included
death during the follow-up period, end stage renal disease
(i.e., need for chronic hemodialysis) and need for long-
term oxygen therapy.
Definitions and classification of the underlying
causes of DAH
The etiologic diagnoses of DAH were specifically defined
and classified into four groups.
Immune causes
The American College of Rheumatology criteria were used
for defining a necrotizing vasculitis. A histological proof ofhage, showing diffuse pulmonary infiltrates; B) Macroscopically
nt in sequential bronchoalveolar lavage aliquots from the same
) Bronchoalveolar lavage fluid stained by Perl’s Prussian blue
lar hemosiderin-laden macrophages. (For interpretation of the
the web version of this article.)
Figure 2 Distribution of the etiology of diffuse alveolar
hemorrhage over three 10-year time periods. There was no
significant change in the proportion of each etiologic group
over time (p Z 0.33). DAH, diffuse alveolar hemorrhage; CHF,
chronic heart failure.
1024 N. de Prost et al.necrotizing vasculitis was required.30e33 The American
Rheumatism Association criteria were used for defining
a connective tissue disease.34,35 The anti-glomerular base-
ment membrane antibody disease (ABMAD; i.e., Good-
pasture’s syndrome) was diagnosed when the serologic test
for anti-glomerular basement membrane antibodies was
positive. Alternative diagnosis was made on the presence of
a linear immunofluorescent glomerular immunoglobulin
deposit.8
Congestive heart failure
Clinical and radiological features suggestive of DAH related
to a congestive heart failure (CHF)36 were an increased left
atrial pressure, as diagnosed by echocardiography-doppler
or right heart catheterization.
Miscellaneous causes
The diagnosis of a barotraumatic-stress capillary failure
due to high transpulmonary pressures (tracheal extubation
or scuba diving) was made in a suggestive context.17,37 For
cancer, the presence of histological evidence was required
in the diagnosis. For infection, positive microbiological or
serological tests allowed for diagnosis. Clotting disorders
were diagnosed by a platelet count less than 150,000 cells/
ml, a patient-to-control subject ratio of activated partial
thromboplastin time greater than 1.5, or a thromboplastin
time less than 60%. The diagnosis of toxin- or drug-induced
disease was established when there was a compatible
chronology after exposure to a known pneumotoxic
substance and required the exclusion of all the other causes
of DAH.38
Idiopathic DAH
Idiopathic DAH was defined when a thorough search for the
above-mentioned causes remained negative.
Data presentation and statistical analysis
Continuous variables were reported as median [25the75th
interquartile range] (IQR 25e75) or mean  SD and
compared with the t test when normally distributed or
otherwise with the ManneWhitney test. Analysis of vari-
ance was used to compare the etiologic groups. Bonferroni
corrected post hoc tests were performed when overall p
value was less than 0.05. The ShapiroeWilk normality test
was performed. Categorical variables were reported as
percentages and compared with the c2 test or the Fischer
Exact test as required. The comparison of the outcome of
each etiologic group of DAH was performed by the
KaplaneMeier method with the log-rank test. Two-tailed p
values less than 0.05 were considered statistically signifi-
cant. Analyses were carried out using Statview statistical
software (SAS Institute Inc., Calasabas, USA).
Results
Etiology of DAH and patient characteristics on
hospital admission
One hundred and sixty-six patients were hospitalized for
suspected DAH over the study period. We included 112patients in the cohort [54 patients were excluded because
of missing data (n Z 10), hemorrhage of bronchial origin
(n Z 43), and discovery of an immunocompromised status
during hospitalization (HIV infection, n Z 1)], including 98
patients who were also included in a previous study.10
The whole DAH triad was observed in only 34% (n Z 38/
112) of the patients. Anemia, as defined by blood hemo-
globin <12 g/dL,39 was only present in 59% (n Z 66/112),
and hemoptysis in 66% (n Z 74/112) of cases. In contrast,
pulmonary infiltrates were almost always present (93%,
n Z 104/112).
There were 24 causes of DAH, which were classified into
four etiologic groups (Table 1): immune, CHF, miscella-
neous and idiopathic. The distribution of the etiologic
groups over time was relatively stable (p Z 0.33, Fig. 2).
Differences in clinical (Table 2) and laboratory (Table 3)
features, based on the etiology of DAH, were observed
upon hospital admission.
Pulmonary-renal syndrome was more frequently present
in immune DAH patients than in others (p < 0.001) and
exhibited the following diagnostic performances [95% CI]
for the diagnosis of immune DAH: sensitivity Z 0.41
[0.25e0.58], specificity Z 0.96 [0.88e0.99], positive
predictive value (PPV) Z 0.84 [0.60e0.97], and negative
predictive value (NPV) Z 0.75 [0.65e0.84].
Immunological tests and histological features
ANCA tests were positive for indirect immunofluorescence
in 86% (n Z 24/28) of patients with vasculitides (Table 4).
Kidney biopsy was performed in 67% (nZ 26/39) of patients
with immune DAH. Histological examination revealed
a necrotizing crescentic glomerulonephritis in 24 cases,
including nine patients with Wegener’s granulomatosis
(WG), nine patients with microscopic polyangiitis (MP), and
five patients with ABMAD, and was normal in one patient
Table 2 Demographic and clinical presentation of 112 patients with DAH upon hospital admission.
Variables All patients
(N Z 112)
Immune
(N Z 39)
CHF
(N Z 33)
Miscellaneous
(N Z 26)
Idiopathic
(N Z 14)
P
Age, year 53 (32e68) 48 (24e64) 64 (46e71)e 45 (28e59) 52 (33e63) 0.019
Male gender 73 (65.2) 19 (48.7) 23 (69.7) 22 (84.6) 9 (64.3) 0.58
Weight loss > 5% 42 (37.5) 24 (61.5) 9 (27.3) 6 (23.1) 3 (21.4) 0.09
Tobacco > 20 pack-years 33 (29.5) 8 (20.5) 10 (30.3) 9 (34.6) 6 (42.8) 0.65
Alcohol use 23 (20.5) 6 (15.4) 6 (18.2) 7 (26.9) 4 (28.6) 0.74
Previous cardiovascular diseasea 51 (45.5) 13 (33.3) 24 (72.7) 8 (30.8) 6 (42.8) 0.17
Previous respiratory diseaseb 27 (24.1) 10 (25.6) 9 (27.3) 5 (19.2) 3 (21.4) 0.94
Anticoagulant treatment 16 (14.3) 1 (2.6) 10 (30.3) 4 (15.4) 1 (7.1) 0.034
Antiaggregant treatment 20 (17.8) 5 (12.8) 5 (15.1) 7 (26.9) 3 (21.4) 0.65
ICU admission 86 (76.8) 26 (66.7) 29 (87.9) 24 (92.3) 7 (50.0) 0.59
Prodromal phase, days 21 (4e181) 53 (21e365) 10 (5e195) 3 (0e9)g 165 (6e440) <0.001
First symptom-admission, daysc 8 (3e21) 18 (10e30) 6 (3e15) 3 (1e4)f 15 (3e75) <0.001
Temperature, C 37.3
(37.0e38.2)
38
(37.0e38.5)
37.3
(37.0e38.0)
37.2
(37.0e37.8)
37.5
(37.2e39.0)
0.15
DAH triadd 38 (33.9) 18 (46.1) 10 (30.3) 7 (26.9) 3 (21.4) 0.55
Hemoptysis 74 (66.1) 23 (59.0) 22 (66.7) 18 (69.2) 11 (78.6) 0.94
Hemoptysis > 200 mL/24 h 9 (8.0) 1 (2.6) 1 (3.0) 6 (23.1) 1 (7.1) 0.039
Use of accessory muscles 31 (27.7) 12 (30.8) 9 (27.3) 6 (23.1) 4 (28.6) 0.96
Crackles 86 (76.8) 30 (76.9) 27 (81.8) 21 (80.8) 8 (57.1) 0.54
Mechanical ventilation 20 (17.8) 6 (15.4) 6 (18.2) 7 (26.9) 1 (7.1) 0.59
Shock 23 (20.5) 6 (15.4) 11 (33.3) 5 (19.2) 1 (7.1) 0.31
Extra-pulmonary symptoms
Cutaneous 30 (26.8) 18 (46.1) 7 (21.2) 4 (15.4) 1 (7.1) 0.07
Bone-joint 16 (14.3) 13 (33.3) 2 (6.1) 0 (0.0) 1 (7.1) 0.004
Gastro-intestinal 12 (10.7) 4 (10.2) 4 (12.1) 3 (11.5) 1 (7.1) 0.97
Neurological 24 (21.4) 11 (28.2) 5 (15.1) 6 (23.1) 2 (14.2) 0.68
Nose-ear-throat 26 (23.2) 16 (41.0) 3 (9.0) 1 (3.8) 6 (42.8) 0.007
Ocular 11 (9.8) 7 (17.9) 1 (3.0) 1 (3.8) 2 (14.2) 0.18
Urinalysis reagent strip
Hematuria 29 (25.9) 25 (64.1) 1 (3.0) 3 (11.5) 0 (0.0) <0.001
Proteinuria 34 (30.3) 25 (64.1) 4 (12.1) 2 (7.7) 3 (21.4) <0.001
Data are presented as mean  SD or median (IQR 25e75) when appropriate, or number (N) and percentage (%). DAH, diffuse alveolar
hemorrhage; CHF, Congestive heart failure.
a Hypertension (n Z 36), coronary heart disease (n Z 22), atrial fibrillation (n Z 13), oblitering arteriopathy of the lower limbs
(n Z 6), stroke (n Z 3).
b COPD (n Z 9), respiratory tract infection (n Z 10), miscellaneous (n Z 8).
c Time elapsed between the first symptom of DAH and hospital admission.
d Defined as anemia (hemoglobin level <12 g/dL), pulmonary infiltrates and hemoptysis.
e p < 0.05 as compared to immune DAH and DAH of miscellaneous causes.
f p < 0.01 as compared to idiopathic and immune DAH.
g p < 0.001 as compared to all other DAH.
Diffuse alveolar hemorrhage: Etiology and outcome 1025with MP. Three patients with negative ANCA tests (one WG
and two MPs) had a positive diagnosis of necrotizing cres-
centic glomerulonephritis. Immunofluorescence was avail-
able in 16 kidney biopsy samples including seven patients
with WG, four with MP and five with ABMAD. Among WG and
MP patients, two patients exhibited a granular IgG, IgM, or
C3 staining pattern on the basal membrane compatible with
immune complexes, and nine had no significant immune
deposit. All five patients with ABMAD exhibited a linear IgG
staining on the glomerular basement membrane. Three of
those patients did not have circulating anti-glomerular
basement membrane antibodies.
Overall, nine lung biopsies were performed and
confirmed the presence of DAH but did not diagnose its
cause in 8/9 cases. Transbronchial biopsies were performedin six cases and revealed mild fibrosis in three patients with
idiopathic DAH, capillaritis in a patient with WG, and did
not assist in diagnosis of two patients. Open chest biopsies
were performed in three patients with immune DAH: one
patient had typical features of WG (i.e., foci of necrosis
and granulomatous inflammation), one had mixed connec-
tive tissue disease with mild interstitial edema and capil-
lary congestion, and another with MP exhibited marked
fibrosis. Immunofluorescence was negative in all cases.Hospital course and outcome
Upon hospital admission, 77% of the patients required ICU
admission (Fig. 3). Twenty patients (18%) underwent
Table 3 Laboratory features of 112 patients with DAH upon hospital admission.
Variables All patients
(N Z 112)
Immune
(N Z 39)
CHF
(N Z 33)
Miscellaneous
(N Z 26)
Idiopathic
(N Z 14)
P
SAPS II 22 (13e35) 21 (12e37) 25 (17e35) 23 (12e38) 15 (6e24) 0.19
LOD score 3 (0e5) 3 (1e5)c 3 (1e4) 3 (0e4) 0 (0e1) 0.027
PaO2/FiO2 ratio 264  108 269  110 274  96 222  102 299  127 0.16
Pulmonary infiltrates on CXR 104 (92.8) 36 (92.3) 33 (100) 24 (92.3) 11 (78.6) 0.97
Unilateral infiltrates 13 (11.6) 1 (2.6) 6 (18.2) 5 (19.2) 1 (7.1) 0.17
Bronchoalveolar lavage
Bloody or pink 94 (83.9) 35 (89.7) 25 (75.7) 24 (92.3) 10 (71.4) 0.92
Total cell count, 103/mLa 350 (195e640) 295 (115e565) 390 (195e682) 340 (200e912) 365 (224e750) 0.80
Macrophages, % 71 (47e82) 68 (45e75) 74 (47e80) 71 (45e87) 78 (51e88) 0.54
Including siderophages, % 68 (47e99) 60 (50e100) 73 (50e91) 39 (2e85)f 100 (83e100) 0.003
Neutrophils, % 15 (4e37) 25 (10e49) 12 (4e25) 12 (4e33) 8 (1e40) 0.18
Lymphocytes, % 5 (2e13) 4 (1e13) 9 (2e19) 5 (1e10) 4 (1e8) 0.25
Eosinophils, % 0 (0e1) 0 (0e4) 0 (0e1) 0 (0e1) 0 (0e1) 0.69
Presence of germs 20 (17.8) 4 (10.2) 6 (18.2) 8 (30.8) 2 (14.3) 0.38
LDH, UNV 1.1 (0.7e1.9) 1.2 (0.7e1.7) 1.2 (0.7e3.1) 1.0 (0.7e2.0) 1.2 (0.7e2.3) 0.93
Glomerular filtration rate,
mL/min
65 (40e101) 43 (13e77)d 55 (40e88) 90 (64e114) 97 (61e108) <0.001
Pulmonary-renal syndromeb 19 (17.0) 16 (41.0) 3 (9.1) 0 (0.0) 0 (0.0) <0.001
Hemoglobinemia, g/dL 10.9  3.0 9.0  2.1e 11.8  2.5 11.5  3.4 13.0  2.7 <0.001
White blood cells count,
103/mL
9.5 (7.0e14.9) 9.6 (6.9e13.0) 11.0 (7.4e16.8) 8.9 (7.0e15.3) 8.3 (6.5e12.6) 0.46
Platelets count, 103/mL 285  139 330  149 285  131 226  142g 265  81 0.027
Data are presented as mean  SD or median (IQR 25e75) when appropriate, or number (N) and percentage (%). DAH, diffuse alveolar
hemorrhage; CHF, Congestive heart failure; UNV, upper normal value; CXR, chest x-ray.
a Cytology was only obtained in 90 patients because the amount of red blood cells in the BAL fluid precluded its analysis in 22 cases.
b As defined by the presence of DAH and the following criteria: hematuria on urinalysis reagent strip, proteinuria > 1 g/L, and
glomerular filtration rate <60 mL/min.
c p < 0.05 as compared to idiopathic DAH.
d p < 0.01 as compared to DAH of idiopathic and miscellaneous causes.
e p < 0.001 as compared to all other groups.
f p < 0.01 as compared to idiopathic DAH.
g p < 0.05 as compared to immune DAH.
Table 4 ANCA-test results in 28 patients with DAH due to
vasculitides.
IIF pattern ELISA specificity MP
(N Z 16)
WG
(N Z 11)
CSS
(N Z 1)
p-ANCA MPO-ANCA 8 2 0
PR3-ANCA 0 0 0
Not reported 3 2 0
c-ANCA MPO-ANCA 0 0 0
PR3-ANCA 0 1 0
Not reported 2 4 0
Nonspecific MPO-ANCA 0 0 0
PR3-ANCA 0 0 0
Not reported 0 1 1
Negative 3 1 0
ANCA, anti-neutrophil cytoplasm antibody; IIF, indirect immu-
nofluorescence; MP, microscopic polyangiitis; WG, Wegener’s
granulomatosis; CSS, Churg and Strauss syndrome; p-ANCA,
ANCA with a perinuclear staining; c-ANCA, ANCA with a cyto-
plasmic staining; MPO-ANCA, ANCA directed against myeloper-
oxydase; PR3-ANCA, ANCA directed against proteinase-3.
1026 N. de Prost et al.invasive mechanical ventilation within the 24 h of hospital
admission and 18 patients (16%) immediate hemodialysis,
which was more frequently required in immune DAH
patients than in others (36% vs 5%; p < 0.01).
The median hospital length of stay was 10 days [6e19],
tending to be longer for immune DAH patients, as compared
to others (p Z 0.09) (Table 5). Invasive mechanical venti-
lation and blood transfusion requirement did not differ
between etiologic groups. In-hospital mortality was higher
for CHF (36.4%) than miscellaneous (26.9%), immune
(17.9%) and idiopathic (7.1%) DAH patients, although not of
statistical significance (Table 5).
Eighty five patients were discharged alive from hospital
and followed up for a median period of nine months [1e48]
(Table 6). Pulmonary fibrosis was diagnosed upon a review
of histologic section in two patients with idiopathic DAH.
Overall, the mortality rate of discharged patients was 14.1%
(n Z 12/85), and was not different between groups.All-cause mortality over the follow-up period
All-cause mortality rate over the follow-up period was 35%
(nZ 39/112), encompassing both in-hospital mortality and
Long-term mortality = 14.7%
( 9/61)
Long-term mortality = 13.6%
(3/22)
Immune DAH n=39
CHF n=33
Miscellaneous n=26
Idiopathic DAH n=14
ICU, n = 86
SAPS II = 25 [16-38]
Hospital mortality = 29.1% (25/86)
Chest Unit, n = 26
SAPS II = 13 [8-24]
Hospital mortality = 7.7% (2/26)
Included patients hospitalized between 1980 and 2009 for 
DAH
n = 112
Figure 3 Flow chart of patients hospitalized for suspected
diffuse alveolar hemorrhage between 1980 and 2009.
Diffuse alveolar hemorrhage: Etiology and outcome 1027mortality in discharged patients. Although not statistically
significant, CHF patients exhibited a higher mortality
(45.4%; n Z 15/33) than miscellaneous (34.6%; n Z 9/26),
immune (30.8%; n Z 12/39) and idiopathic (21.4%; n Z 3/
14) DAH patients (Fig. 4).
Discussion
Since the comprehensive review published in 1984 by
Leatherman et al.,2 this is the largest series to describe the
causes of DAH and their relative frequency and particular
presentation in unselected patients. Based on a simple
classification of DAH in four groups, the main results of this
study are as follows: 1) Patients with immune, CHF,
miscellaneous, and idiopathic DAH exhibited distinct clin-
ical and laboratory features; 2) In-hospital mortality was
24.1%, ranging from 7.1% in patients with idiopathic DAH to
36.4% in those with CHF.
Diagnosis of DAH
The typical presentation of DAH is a triad of anemia,
pulmonary infiltrates on chest x-ray, and hemoptysis.2 In
the current series, this triad was only present in 34% of
patients, although most had severe diseases. Therefore, to
make a diagnosis of DAH on the basis of clinical and
radiologic criteria could be challenging.Table 5 Hospital course of 112 patients with DAH.
Variables All patients
(N Z 112)
Immune
(N Z 39)
Hospital LOS, days 10 (6e19) 16 (7e24)
Mechanical ventilation 30 (26.8) 11 (28.2)
Hemodialysis 18 (16.1) 14 (35.9)
Blood transfusion 48 (42.8) 24 (61.5)
In-hospital mortality 27 (24.1) 7 (17.9)
Data are presented as median (IQR 25e75) or number (N) and percent
failure; LOS, length of stay.Early bronchoscopy with bronchoalveolar lavage is indi-
cated in most of patients suspected of having DAH in order
to confirm the diagnosis and to rule out infection.1,3
Indeed, we found that DAH could be confirmed immedi-
ately by a macroscopically bloody or pink BAL in 84% of
cases. Alternatively, usually in chronic and mild DAH, it can
be diagnosed using a score (i.e., the Golde score) based on
the semiquantitative hemosiderin content of alveolar
macrophages.19,40Etiologies of DAH and their relative frequency
More than 100 causes of DAH have been described (Table 1
of the online supplement). Yet, the most common etiology
is still unknown. In the present series, we identified 24
causes, which were classified into four groups based on
their relative frequency: immune, CHF, miscellaneous, and
idiopathic DAH.
Immune DAH was the largest etiologic group, accounting
for 35% of all causes. Small-vessel vasculitides, predomi-
nantly MP and WG, were the main subset of immune DAH
(72%). Among 34 cases of DAH, Travis et al. initially repor-
ted 14 vasculitides, including 11 cases of WG and three
cases of systemic necrotizing vasculitis.12 Our study
confirms that ANCA-associated diseases are now the main
subset of immune DAH with a small proportion of WG.
Indeed, DAH was the first cause of ICU admission, observed
in 37% of cases, in patients with small-vessel vasculitis
having acute life-threatening manifestations.41 Five
patients had ABMAD, accounting for 13% of immune and 4%
of all DAH. In contrast, Leatherman et al. reported 10 cases
of ABMAD out of 26 patients, and likely overestimated the
frequency of this disease, as their cohort was based on
a combination of literature review and analysis of cases
encountered by the authors.2 Finally, four of six patients
with connective tissue disorder-associated DAH had
systemic lupus erythematosus (SLE). DAH is associated with
SLE in about four percent of cases and represents about 22%
of respiratory complications. In a previous series of patients
with SLE-related DAH, the diagnosis of SLE was established
before the onset of DAH in 80% of cases allowing for early
targeted management.6
CHF affected 29% of all patients and was the most
frequent diagnosis among patients with non-immune DAH.
Those patients exhibited overt DAH, as opposed to usual
cardiogenic pulmonary edemas, as attested by a macro-
scopically bloody/pink BAL in 76% of cases and highCHF
(N Z 33)
Miscellaneous
(N Z 26)
Idiopathic
(N Z 14)
P
8 (6e18) 8 (4e15) 9 (7e15) 0.09
11 (33.3) 7 (26.9) 1 (7.1) 0.51
2 (6.1) 2 (7.7) 0 (0.0) 0.006
10 (30.3) 10 (38.5) 4 (28.6) 0.32
12 (36.4) 7 (26.9) 1 (7.1) 0.30
age (%). DAH, diffuse alveolar hemorrhage; CHF, Congestive heart
Table 6 Outcome of discharged patients (N Z 85) over the follow-up period.
Variables All patients
(N Z 85)
Immune
(N Z 32)
CHF
(N Z 21)
Miscellaneous
(N Z 19)
Idiopathic
(N Z 13)
P
Clinical relapse of DAH 19 (22.3) 10 (31.2) 2 (9.5) 3 (15.8) 4 (30.8) 0.18
LTOT 5 (5.9) 1 (3.1) 0 (0.0) 1 (5.3) 3 (23.1) 0.026
End stage renal disease 7 (8.2) 7 (21.9) 0 (0.0) 0 (0.0) 0 (0.0) 0.008
Follow-up period duration,
months
9 (1e48) 16 (1e48) 3 (1e25)** 13 (1e88) 70 (5e157) 0.015
Mortality 12 (14.1) 5 (15.6) 3 (14.3) 2 (10.5) 2 (15.4) 0.90
Data are presented as median (IQR 25e75) or number (N) and percentage (%). DAH, diffuse alveolar hemorrhage; CHF, Congestive heart
failure; LTOT, long-term oxygen therapy; **p < 0.01 as compared to idiopathic DAH.
1028 N. de Prost et al.percentages of BAL siderophages. Interestingly, only four of
those patients had mitral stenosis, which was formerly
considered to be the main cause of CHF-related DAH.1,42
Instead, most of those patients had congestive heart
failure due to systolic or diastolic dysfunction of the left
ventricle. This finding is in keeping with the increasing
incidence and prevalence in chronic heart failure, likely
related to the increase in life span and effective treatment
of hypertension and coronary artery disease.43
Therewere 13 causes ofmiscellaneous DAH in 26 patients.
Although most of those causes had already been reported
(Table 1 of the online supplement), our study allows for the
assessment of the proportion of frequent causes of DAH, as
opposed to rare and anecdotal ones. Indeed, infections,
barotraumas, and clotting disorders accounted for 77% of the
diagnoses within this etiologic group.
Infection
The pathogen retrieved in most of the infectious causes was
Staphylococcus aureus (n Z 5), including two methicillin-
resistant and three Panton-Valentine leukocidin (PVL)
producing strains. This is consistent with previous reports
emphasizing the hemorrhagic presentation of pneumonia
involving those strains and confirms that S. aureus is prev-
alent among DAH patients presenting signs of acute0.4
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Figure 4 KaplaneMeier curve of survival probability over
time for idiopathic (dotted line), immune (dashed line),
miscellaneous (dotted/dashed line), and congestive heart
failure-related (CHF, continuous line) diffuse alveolar hemor-
rhage (DAH). Overall, there was no statistical difference
between groups (p Z 0.25 by the log-rank test).infection.44e46 One patient, with recent travel history to
the French Antilles, had a leptospirosis, frequently under-
estimated in the setting of DAH.21 Although it is mainly
endemic in tropical areas,47 it can occur worldwide. One
patient, who had recently traveled to Democratic Republic
of the Congo, had a DAH related to pulmonary filariasis.
Dirofilaria immitis, often referred to as the canine heart-
worm, is a vascular parasite that is prevalent in dogs in the
United States,48 and in South America.49 This parasite is
usually transmitted to humans by mosquito bites and causes
pulmonary and subcutaneous nodules,50 and eosinophilia.
To the best of our knowledge, there is no previously pub-
lished case of D. immitis infection revealed by DAH.
Barotrauma
Barotrauma-related DAH have been previously described in
various situations associated with high transpulmonary
pressures such as scuba diving,16 upper airway obstruc-
tion,51 and mechanical ventilation with major patient-
ventilator asynchronies, usually following general
anesthesia.17
Iatrogenic and toxic
Anticoagulant treatments were associated with other cau-
ses in about 15% of the cases and were likely to have trig-
gered or aggravated DAH in these cases, especially if
overdosed or when associated with anti-platelet treat-
ments. We only reported three cases of toxic- and drug-
induced DAH, and surprisingly no case of DAH related to
cocaine smoking or inhalation, a common cause of DAH.52
Current and past drug intake is crucial in the evaluation
of DAH patients, as withdrawal of the culprit drug or toxic
can reverse a life-threatening situation.38
Finally, idiopathic DAH is a rare condition with an
unknown incidence and prevalence in the population. In the
current series, it accounted for 12% of the DAH. There are
more than 500 cases of idiopathic DAH published in the
literature. However, many patients previously reported to
have idiopathic DAH were likely misdiagnosed, having DAH
of other origins.53 They would currently be categorized
differently with the advent of newer diagnostic tools.54
Presentation and diagnosis of the underlying causes
of DAH
Classification of DAH in four etiologic groups allowed us to
depict specific clinical and laboratory patterns.
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Patients having immune DAH exhibited more extra-
pulmonary symptoms, such as cutaneous, bone-joint, and
ear-nose- throat symptoms, more urinary sediment abnor-
malities, and worse renal function than others upon
hospital admission. Pulmonary-renal syndrome was associ-
ated with a high specificity (96%), but a low sensitivity (41%)
for the diagnosis of immune DAH. Except for SLE-related
DAH, which was previously shown to have an abrupt
presentation,6 the onset of immune DAH was usually
subacute, with a median duration of 18 days between the
first respiratory symptom and hospital admission. This
might have contributed to more important blood spoliation
and thus deeper anemia in patients with immune DAH as
compared to others. Miscellaneous DAH patients had
shorter onset of initial respiratory symptoms from time of
hospital admission than others. As a result, they had less
BAL siderophages, as hemosiderin appears at least 48 h
after bleeding.55 Most of barotrauma-related DAH occurred
after a short period of general anesthesia in healthy
subjects (n Z 4/6), as previously described.17,51,56
Idiopathic DAH patients tended to exhibit lower LOD
scores and required less frequent invasive mechanical
ventilation than others. Those patients had more BAL
siderophages than others, suggesting that they had expe-
rienced chronic/latent alveolar hemorrhage before admis-
sion. Indeed, most patients with idiopathic DAH experience
recurrent episodes of DAH over life, frequently starting
during childhood.53,54
Specific laboratory tests and histological approach
Since the ANCA era, routine serological screening for ANCA
allowed using a less invasive diagnostic strategy in
a majority of patients.57 Indeed, only 34% of our patients
underwent lung or kidney biopsies, which were more
frequently performed in patients with immune than in
those with non-immune DAH (30/39 vs 8/73; p < 0.001).
The indications and the diagnostic yield of kidney and lung
biopsies in the setting of DAH are however distinct. A renal
biopsy is indicated in presence of rapidly progressive renal
function decline associated with hematuria and/or
proteinuria. Renal histology contributes in the diagnosis,
particularly when ANCA test is negative, but also in the
decision of immunosuppressive therapy and in renal prog-
nosis.58 In contrast, the benefit/risk ratio associated with
lung biopsy is not clear, particularly in patients with acute
respiratory failure. The interest of lung biopsy for diag-
nosing the cause of DAH was weak in previous studies.12 If
the underlying cause of DAH remains elusive after a thor-
ough clinical evaluation, then, a biopsy approach might be
required. A surgical lung biopsy should be considered when
the level of suspicion for extra-pulmonary lesions (e.g.,
kidney or skin) is low.3 In such cases, specimens should be
processed for immunofluorescence staining and bacterial
culture.57Complications and outcome of DAH
The reported mortality of DAH syndromes is high, ranging
generally from 20% to 50%.4e6,13,59 However, the outcome
varies depending on the cause. For instance, in a series of28 cases of ABMAD with DAH, all patients were discharged
alive from hospital.14 In contrast, DAH related to SLE
exhibited particularly poor outcome with mortality rates
over 50%.6 In the current series, in-hospital mortality rates
dramatically differed among the different etiologic
groups, ranging from 7.1% in idiopathic DAH to 36.4%
in CHF.
CHF-related DAH mortality is likely related to older age
and associated cardiovascular comorbidity. Previous
cardiovascular disease was present in 72.7% of patients
with CHF, suggesting that DAH was related to acute heart
failure that frequently complicated an underlying chronic
heart disease. The overall mortality rate of this subgroup of
patients was 45.4% over the follow-up period, suggesting
that DAH is a sign of end stage chronic heart failure, as
previously discussed.10
Although all patients with barotrauma-related DAH were
treated successfully, seven patients with miscellaneous
causes, mainly infection and cancer, died. Three of those
had a S. aureus infection, including two PVL-producing
strains. Previous series of patients hospitalized for
community-acquired pneumonias due to PVL-producing S.
aureus reported mortality rates between 56 and 75%.46,60
In-hospital mortality of patients with immune DAH was
17.9% in our series, which is lower than in previous
series.5,6,13,59 Patients with immune DAH exhibited severe
acute illnesses related to pulmonary-renal syndromes. The
relatively good outcome, as compared to previous series of
immune DAH and DAH of other causes, illustrates the
sensitivity of immune DAH to early aggressive immunosup-
pressive treatment.2,5,13,61 Moreover, renal recovery in
patients presenting with acute renal failure is maximized in
patients receiving early adequate treatment.8,62 In this
series, end stage renal disease occurred in seven out of 24
patients who had documented necrotizing glomerulone-
phritis. In patients who required immediate hemodialysis,
renal death was avoided in 50% of cases, a stark contrast to
a previous study reporting no renal survival in this subgroup
of patients.8
Patients with idiopathic DAH had a good prognosis. In-
hospital mortality rate was 7.1%, and two patients died
over the follow-up period. Many reports emphasized the
better prognosis of adult onset diseases,54 compared to
children.63 For instance, Chryssanthopoulos et al. reported
a mortality rate of 60% associated with a mean survival time
of three years in a series of 30 children.63 Steroid treatment
is commonly used, particularly in the acute phase of the
disease.54,64 Currently, there are no codified long-term
treatment strategies to prevent recurrence of disease and
progressive pulmonary fibrosis leading to deterioration of
lung function.
While immunological tests and organ biopsy results are
pending, deciding whether to initiate an immunosuppres-
sive treatment or not is challenging. Ideally, immune DAH
patients should receive such treatment as soon as possible,
as it is life- and renal function-saving. In contrast, immu-
nosuppressive treatment could be deleterious for non-
immune DAH patients. Differences in the clinical presen-
tation of patients with immune and non-immune DAH
recently allowed our group to build a predictive clinical
scale in order to help clinicians in the initial steps of DAH
patients management.65
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Several limitations of the current series must be acknowl-
edged. First, this is a retrospective study conducted over
a 30-year period, during which diagnostic procedures,
patients management and global quality of care may have
varied. Missing data were however limited by excluding
patients who had incomplete medical charts (n Z 10).
Second, it is a single-center study with a limited number of
patients included in each subgroup, which limits the
potential generalization of our conclusions. Third, some
(nZ 98) of the patients included in the current study were
also included in a previously published one.10 However, the
methods and data presented in these two studies are
different. Our previous study aimed at identifying factors
associated with hospital and long-term mortality of DAH
patients10 while the current one not only focused on the
differential presentation of four etiologic groups, but also
provided a detailed description of diagnostic strategies and
outcomes.
In conclusion, we report a large series of unselected
patients hospitalized for DAH. The underlying causes of DAH
were classified into four etiologic groups that exhibited
distinct and easily identifiable clinical and laboratory
features, thus making easier early identification by clini-
cians. In-hospital mortality varied between 7.1% in patients
having idiopathic DAH to 36.4% in patients with DAH related
to CHF.Conflict of interest
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